FindTrial
Sign In

Comparison of long-term tumor prognosis between clinical T4 and T3 in patients with pathological stage IIA rectal cancer after neoadjuvant chemotherapy

Comparison of long-term tumor prognosis between clinical T4 and T3 in patients with pathological stage IIA rectal cancer after neoadjuvant chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080381
Enrollment
Unknown
Registered
2024-01-29
Start date
2024-01-30
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Interventions

Case series:None

Sponsors

Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ?Rectal cancer patients diagnosed clinically as T3 or T4 from January 2014 to September 2018, with postoperative pathological stage IIA. ?Aged between 18 and 80 years. ?No distant metastasis. ?Clinical staging meeting the criteria for neoadjuvant therapy, and completion of neoadjuvant therapy.

Exclusion criteria

Exclusion criteria: ?Pathological types include squamous cell carcinoma, signet ring cell carcinoma, etc. ?Multiple primary tumors, unclear clinical diagnosis. ?R0 resection not achieved.

Design outcomes

Primary

MeasureTime frame
5-year overall survival (OS);5-year disease-free survival rate (DFS);—

Countries

China

Contacts

Public ContactHui Wang

The Sixth Affiliated Hospital, Sun Yat-sen University,

wang89@mail.sysu.edu.cn+86 139 2642 4886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026